Home » Topics » BioWorld Science

BioWorld Science
RSS

CD38 inhibitors discovered at Napa Therapeutics, Buck Institute

May 6, 2022

Silverback Therapeutics synthesizes TGFR-1 inhibitors and antibody-drug conjugates

May 6, 2022

Enliven Therapeutics describes new Bcr-Abl kinase inhibitors

May 6, 2022

BCY-6033: EphA2-targeting BTC with efficacy in NSCLC PDX models

May 6, 2022

Researchers discover HDAC1 as the cause of immune abnormalities in autistic mouse models

May 5, 2022

DGKk gene therapy rescues brain lipid profiles and long-term behavior in fragile X syndrome mice

May 5, 2022

ALTA-2530 shows preclinical efficacy as potential treatment of bronchiolitis obliterans syndrome

May 5, 2022

FDA awards orphan drug designation to AB-001 for pancreatic cancer and AML

May 5, 2022

CDK7 inhibitor GTAEXS-617 shows potent antitumor activity in vivo

May 5, 2022

TRAIL protein levels may predict response to acamprosate in alcohol use disorder

May 5, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...